Review anchor
Peroxisome proliferator-activated receptor
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Peroxisome proliferator-activated receptor
CHEMBL3559683
PROTEIN FAMILY
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Peroxisome proliferator-activated receptor as ChEMBL target CHEMBL3559683, mapped to UniProt P37231. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3559683
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P37231
Peroxisome proliferator-activated receptor gamma
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Peroxisome proliferator-activated receptor matters
Peroxisome proliferator-activated receptor is reviewed as Peroxisome proliferator-activated receptor gamma (UniProt P37231); Peroxisome proliferator-activated receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 85 compounds, and 33 assays, with lead potency reaching pChEMBL 6.5.
Protein context
Peroxisome proliferator-activated receptor gamma
Peroxisome proliferator-activated receptor gamma Sequence length is 505 aa.
Review this target as Peroxisome proliferator-activated receptor, mapped to UniProt P37231. ChEMBL maps the protein component as Peroxisome proliferator-activated receptor gamma. Sequence length is 505 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P37231
Protein
Disease context
cardiovascular disease
Peroxisome proliferator-activated receptor shows approved-linked disease relevance led by cardiovascular disease. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BEZAFIBRATE.
Start review with cardiovascular disease because it currently carries approved-linked support. Linked drugs include BEZAFIBRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 85 compounds, and 33 assays for this target. The dominant activity type is EC50. CHEMBL458899 is the current potency anchor at pChEMBL 6.5.
Use CHEMBL458899 as the tractability anchor when discussing potency (pChEMBL 6.5).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 6.5
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Peroxisome proliferator-activated receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P37231, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why cardiovascular disease is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
85
Total Compounds
33
Total Assays
1
Approved Drugs
EC50: 25.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL458899
|
6.5 | EC50 | — |
|
|
No preferred name
CHEMBL264374
|
6.0 | EC50 | Clinical |
|
|
No preferred name
CHEMBL516827
|
5.9 | EC50 | — |
|
|
No preferred name
CHEMBL121
|
5.8 | EC50 | Approved |
|
|
No preferred name
CHEMBL2159607
|
5.3 | EC50 | — |
Source Header